journal
MENU ▼
Read by QxMD icon Read
search

Biology of Blood and Marrow Transplantation

journal
https://www.readbyqxmd.com/read/28734876/t-cell-depletion-as-an-alternative-approach-for-patients-55-years-undergoing-allogeneic-stem-cell-transplantation-as-curative-therapy-for-hematologic-malignancies
#1
Ann A Jakubowski, Erica Petrlik, Molly Maloy, Patrick Hilden, Esperanza Papadopoulos, James W Young, Farid Boulad, Hugo Castro-Malaspina, Roni Tamari, Parastoo B Dahi, Jenna Goldberg, Guenther Koehne, Miguel-Angel Perales, Craig S Sauter, Richard J O'Reilly, Sergio Giralt
T cell depleted allogeneic hematopoietic stem cell transplantation (TCD HSCT) is curative treatment for hematologic malignancies in adults, shown to reduce graft vs. host disease (GVHD) without increased relapse. We retrospectively reviewed a single center, 11yr experience of 214 patients ≥55yrs to determine tolerability and efficacy in the older adult. The majority (70%) had myeloid diseases and most acute leukemias were in remission. Median age was 61 yrs with related and unrelated donors > 8/10 HLA matched...
July 19, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28733266/long-term-results-of-high-dose-therapy-and-autologous-stem-cell-transplantation-for-mantle-cell-lymphoma-effectiveness-of-maintenance-rituximab
#2
Matthew G Mei, Thai M Cao, Lu Chen, Joo Song, Tanya Siddiqi, Ji-Lian Cai, Leonardo T Farol, Monzr M Al Malki, Amandeep Salhotra, Ibrahim Aldoss, Joycelynne Palmer, Alex F Herrera, Jasmine Zain, Leslie L Popplewell, Robert W Chen, Steven T Rosen, Stephen J Forman, Larry Kwak, Auayporn P Nademanee, Lihua E Budde
High-dose therapy followed by autologous stem cell transplantation (ASCT) can improve outcomes for mantle cell lymphoma (MCL) but is associated with a high incidence of relapse. A retrospective study of 191 MCL patients who underwent ASCT at City of Hope was performed to examine prognostic factors for outcomes following ASCT. For all patients, the 5-year overall survival (OS) was 71% (confidence interval [CI]: 63% - 77%) and progression-free survival (PFS) was 53% (CI: 45% - 60%). The 5-year cumulative incidence of relapse was 41% (CI: 34% - 48%) with a continuous pattern of relapse events occurring at a median of 2...
July 18, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28733265/-outcomes-of-hematopoietic-stem-cell-transplantation-at-a-limited-resource-center-in-mexico-are-comparable-to-those-in-developed-countries
#3
Eucario Leon Rodriguez, Monica M Rivera Franco
The first hematopoietic stem cell transplantation (HSCT) in Mexico was performed at our Institution in 1980. Eighteen years later our HSCT Program was restructured to reduce transplant related mortality (TRM) and improve overall survival (OS). The aim of this study was to describe outcomes of HSCT at our institution despite limited resources. Consecutive patients undergoing HSCT, from November 1998 to February 2017, were retrospectively analyzed at the National Institute of Medical Sciences and Nutrition Salvador Zubiran in Mexico City...
July 18, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28733264/the-impact-of-toxicities-on-first-year-outcomes-after-ex-vivo-cd34-selected-allogeneic-hematopoietic-cell-transplantation-in-adults-with-hematologic-malignancies
#4
Satyajit Kosuri, Diego Adrianzen Herrera, Michael Scordo, Gunjan L Shah, Christina Cho, Sean M Devlin, Molly A Maloy, Jimmy Nieves, Taylor Borrill, Dean C Carlow, Scott T Avecilla, Richard C Meagher, Richard J O'Reilly, Esperanza B Papadopoulos, Ann A Jakubowski, Guenther Koehne, Boglarka Gyurkocza, Hugo Castro-Malaspina, Brian C Shaffer, Roni Tamari, Sergio A Giralt, Miguel-Angel Perales
Factors that impact first year morbidity and mortality in adults undergoing myeloablative allogeneic hematopoietic cell transplantation with ex-vivo CD34+ selection have not been previously reported. We assessed all toxicities ≥ grade 3 from the start of conditioning to date of death, relapse, or last contact in 200 patients during the first year post-transplantation, identifying 1885 individual toxicities among 17 organ-based toxicity groups. The most prevalent toxicities in the 1(st) year were of infectious, metabolic, hematologic, oral/GI, hepatic, cardiac and pulmonary etiologies...
July 18, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28733263/consolidation-therapy-for-newly-diagnosed-pediatric-high-risk-neuroblastoma-patients-using-busulfan-melphalan-autologous-hematopoietic-cell-transplant-anti-gd2-antibody-gm-csf-il-2-and-haploidentical-nk-cells
#5
Aimee C Talleur, Brandon M Triplett, Sara Federico, Ewelina Mamcarz, William Janssen, Jianrong Wu, David Shook, Wing Leung, Wayne L Furman
The treatment of pediatric high-risk neuroblastoma is intensive and multimodal. Despite the introduction of immunotherapy for minimal residual disease, survival rates remain suboptimal and new therapies are needed. As part of a phase 2 trial, we are using a consolidation therapy regimen which combines a busulfan/melphalan conditioning schema, autologous hematopoietic cell transplant (AHCT), and experimental immunotherapy with hu14.18K322A (a humanized anti-GD2 monoclonal antibody), GM-CSF, and IL-2, with or without the adoptive transfer of haploidentical natural killer cells (NKs)...
July 18, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28729150/impact-of-dendritic-cell-recovery-on-outcomes-after-umbilical-cord-blood-and-sibling-donor-transplantation-for-hematologic-malignancies
#6
Waseem Touma, Claudio G Brunstein, Michael R Verneris, Qing Cao, Julie Curtsinger, Jeffrey S Miller, Veronika Bachanova
Dendritic cells (DCs) orchestrate immune responses after allogeneic hematopoietic cell transplantation (HCT). We studied the association of donor myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) recovery in the landmark analysis of umbilical cord blood (UCB) and matched related donor (RD) HCT. Eighty patients (42 UCB and 38 RD recipients) with a day 100 (D+100) blood sample were included in the analysis. Median age was 51 years (20-71). Most patients had acute leukemia (50%) or lymphoma (23%) and received reduced-intensity conditioning (75%)...
July 17, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28729149/is-my-child-safe
#7
Susan E Prockop
No abstract text is available yet for this article.
July 17, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28729148/clinical-grade-expanded-tregs-prevent-gvhd-while-allowing-a-powerful-t-cell-dependent-gvl-effect-in-murine-models
#8
B Del Papa, L Ruggeri, E Urbani, S Baldoni, D Cecchini, T Zei, R Iacucci Ostini, B Crescenzi, A Carotti, A Pierini, P Sportoletti, P Di Bartolomeo, F Falzetti, C Mecucci, A Velardi, M F Martelli, M Di Ianni
We developed a GMP-compatible expansion protocol, to improve number and purity of Tregs available for clinical trials. Six clinical grade separation procedures were performed, followed by expansion with high-dose interleukin (IL)-2, anti-CD3/anti-CD28 TCR stimulation and rapamycin for 19 days achieving a median of 8.5 fold (6.25-13.7) expansion. FOXP3 expression was stably maintained over the culture period, while the percentage of CD127 was significantly reduced. The in vitro suppression assay showed a strong MLR inhibition...
July 17, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28729147/adult-umbilical-cord-blood-transplantation-using-myeloablative-thiotepa-total-body-irradiation-and-fludarabine-conditioning
#9
Sarah Anand, Samantha Thomas, Kelly Corbet, Cristina Gasparetto, Gwynn D Long, Richard Lopez, Ashley K Morris, David A Rizzieri, Keith M Sullivan, Anthony D Sung, Stefanie Sarantopoulos, Nelson J Chao, Mitchell E Horwitz
Treatment related mortality (TRM) remains elevated in adult patients undergoing umbilical cord blood (UCB) transplantation, including an early rise in TRM suggestive of excessive toxicity associated with the standard myeloablative total body irradiation (TBI), fludarabine, and cyclophosphamide regimen. In an attempt to reduce regimen-related toxicity, we previously studied a modified myeloablative regimen with total body irradiation (1350 cGy) and fludarabine (160 mg/m(2)); TRM was decreased but neutrophil engraftment was suboptimal...
July 17, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28712935/phase-ii-study-of-sequential-infusion-of-dli-and-cytokine-induced-killer-cells-for-patients-relapsed-after-allohsct
#10
Martino Introna, Federico Lussana, Alessandra Algarotti, Elisa Gotti, Rut Valgarsdottir, Caterina Micò, Anna Grassi, Chiara Pavoni, Maria Luisa Ferrari, Federica Delaini, Elisabetta Todisco, Irene Cavattoni, Sara Deola, Ettore Biagi, Adriana Balduzzi, Attilio Rovelli, Matteo Parma, Sara Napolitano, Giusy Sgroi, Emanuela Marrocco, Paolo Perseghin, Daniela Belotti, Benedetta Cabiati, Giuseppe Gaipa, Josée Golay, Andrea Biondi, Alessandro Rambaldi
Seventy-four patients relapsed after allogeneic stem cell transplantation were enrolled in a phase IIA study and treated with the sequential infusion of donor lymphocytes (DLI) followed by cytokine induced killer (CIK) cells. Seventy-three patients were available for the intention to treat analysis. At least one infusion of CIK cells was given to 59 patients, while 43 patients received the complete cell therapy planned (58%). Overall, 12 patients (16%) developed acute GvHD (aGvHD, of grade I-II in 7 cases and grade III-IV in 5)...
July 13, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28712934/donor-lymphocyte-infusions-used-to-treat-mixed-chimeric-and-high-risk-patient-populations-in-the-relapsed-and-non-relapsed-settings-after-allogeneic-transplant-for-hematologic-malignancies-are-associated-with-high-5-year-survival-if-persistent-full-donor-chimerism
#11
Lauren E Caldemeyer, Luke P Akard, John R Edwards, Anand Tandra, Dawn R Wagenknecht, Michael J Dugan
Mixed chimerism (MC), a persistent or increasing number of host cells after allogeneic hematopoietic stem cell transplant (HSCT), is a predictor of disease relapse. Donor lymphocyte infusions (DLI) have the potential to enhance the graft vs. malignancy (GvM) effect, reducing the risk of relapse in patients with MC. Hence, in addition to utilizing DLI in the relapsed setting, there is a motivation to pursue pre-emptive DLI for patients in complete remissions (CR) after HSCT. To assess the safety and efficacy of DLI, records of 86 patients who received DLI between 2003 and 2015 at a single institution were studied retrospectively...
July 13, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28711728/allogeneic-blood-or-marrow-transplantation-with-post-transplantation-cyclophosphamide-as-graft-versus-host-disease-prophylaxis-in-multiple-myeloma
#12
Nilanjan Ghosh, Xiaobu Ye, Hua-Ling Tsai, Javier Bolaños-Meade, Ephraim J Fuchs, Leo Luznik, Lode J Swinnen, Douglas E Gladstone, Richard F Ambinder, Ravi Varadhan, Satish Shanbhag, Robert A Brodsky, Ivan M Borrello, Richard J Jones, William Matsui, Carol Ann Huff
Allogeneic blood or marrow transplantation (alloBMT) may lead to long-term disease control in patients with multiple myeloma (MM). However, historically, the use of alloBMT in MM has been limited by its high non-relapse mortality (NRM) rates primarily from graft versus host disease (GVHD). We previously demonstrated that post-transplantation cyclophosphamide (PTCy) decreases the toxicities of both acute and chronic GVHD rates following alloBMT. Here we examine the impact of PTCy in MM patients undergoing alloBMT at Johns Hopkins Hospital...
July 12, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28711727/a-chemotherapy-only-regimen-of-busulfan-melphalan-and-fludarabine-and-rabbit-atg-followed-by-allogeneic-t-cell-depleted-hematopoietic-stem-cell-transplants-for-the-treatment-of-myeloid-malignancies
#13
Barbara Spitzer, Ann A Jakubowski, Esperanza B Papadopoulos, Kirsten Fuller, Patrick D Hilden, James W Young, Juliet Barker, Guenther Koehne, Miguel-Angel Perales, Katharine C Hsu, Marcel R M van den Brink, Nancy A Kernan, Susan E Prockop, Andromachi Scaradavou, Hugo Castro-Malaspina, Richard J O'Reilly, Farid Boulad
We sought to develop a myeloablative chemotherapeutic regimen to secure consistent engraftment of T-cell depleted (TCD) hematopoietic stem cell transplants (HSCT) without the need for total body irradiation, thereby reducing toxicity, while maintaining low rates of GvHD and without increasing relapse. We investigated the myeloablative combination of busulfan and melphalan, with the immunosuppressive agents fludarabine and rabbit anti-thymocyte gloubin (r-ATG) as cytoreduction prior to a T-cell depleted HSCT...
July 12, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28711726/-if-all-you-have-is-a-hammer-%C3%A2-transplants-for-myelodysplastic-syndrome-mds-after-hypomethylating-agents-hma-fail
#14
Alison Wakoff Loren
No abstract text is available yet for this article.
July 12, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28694183/stat3-expression-in-host-myeloid-cells-controls-gvhd-severity
#15
Evelyn C Nieves, Tomomi Toubai, Daniel C Peltier, Katherine Oravecz-Wilson, Chen Liu, Hiroya Tamaki, Yaping Sun, Pavan Reddy
Professional antigen presenting cell (APCs) are important modulators of acute graft-versus-host disease (GVHD). Although dendritic cells (DCs) are most potent APC subset, other myeloid cells, especially macrophages (MFs) and neutrophils have recently been shown to play a role in the severity of GVHD. However, the critical molecular mechanisms that determine the functions of myeloid cells in GVHD are unclear. Signal transducer and activator of transcription 3 (STAT3) is a master transcription factor that plays a crucial role in regulating immunity...
July 7, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28694182/allogeneic-hematopoietic-stem-cell-transplantation-with-myeloablative-conditioning-is-associated-with-favorable-outcomes-in-mixed-phenotype-acute-leukemia
#16
Bartlomiej M Getta, Mikhail Roshal, Junting Zheng, Jae H Park, Eytan M Stein, Ross Levine, Esperanza B Papadopoulos, Ann A Jakubowski, Nancy A Kernan, Peter Steinherz, Richard J O'Reilly, Miguel-Angel Perales, Sergio A Giralt, Martin S Tallman, Brian C Shaffer
Mixed phenotype acute leukemia (MPAL) represents a poorly characterized group of acute leukemias that lack an accepted therapeutic approach and are typically associated with poor outcomes. We present our experience of genomic profiling, pre-transplant therapy and transplant outcomes for 36 well characterized pediatric and adult patients with MPAL defined according to the 2016 WHO leukemia update. A predominance of ALL-associated mutations and cytogenetic abnormalities was noted. Remission rates after induction appeared comparable among adults (20/23) and children (11/13) and among those who received ALL (10/11) or AML-type (21/25) induction...
July 7, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28688919/haploidentical-hematopoietic-cell-transplant-with-post-transplant-cyclophosphamide-and-peripheral-blood-stem-cell-grafts-in-older-adults-with-aml-or-mds
#17
Michael Slade, John F DiPersio, Peter Westervelt, Ravi Vij, Mark A Schroeder, Rizwan Romee
Many hematologic malignancies are diseases of aging and the use of hematopoietic cell transplant (HCT) is growing rapidly among older adults. Modern post-transplant cyclophosphamide (PTCy) protocols with haploidentical (haplo) donors have dramatically expanded the donor pool for patients requiring HCT. Initial studies were performed with bone marrow grafts, which require the donor to undergo anesthesia during harvest. However, the use of mobilized peripheral blood stem cells (PBSC) may be desirable, especially with older donors...
July 5, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28688918/a-time-to-event-ratio-to-predict-outcome-in-patients-with-aml-undergoing-allogeneic-hematopoietic-cell-transplantation
#18
Celalettin Ustun, Todd E DeFor, Armin Rashidi, Steven Devine, Jeffrey Miller, Daniel Weisdorf
No abstract text is available yet for this article.
July 5, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28688917/real-world-economic-burden-associated-with-transplant-related-complications
#19
M A Perales, M Bonafede, Q Cai, P M Garfin, D McMorrow, N C Josephson, A Richhariya
Approximately 20,000 hematopoietic cell transplantation (HCT) procedures are performed in the US annually. Real-world evidence on the costs associated with post-transplant complications are limited. Patients with hematologic malignancies aged ≥18 years undergoing auto-HCT or allo-HCT between January 1, 2011 and June 30, 2014 were identified in the Truven Health MarketScan(®) Research Databases. Patients were required to have 12 months of continuous medical and pharmacy enrollment pre- and post-HCT with the exception that patients with evidence of inpatient death within 12 months post-HCT were also included...
July 5, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28687394/umbilical-cord-blood-cytomegalovirus-serostatus-does-not-have-an-impact-on-outcomes-of-umbilical-cord-blood-transplantation-for-acute-leukaemia
#20
Olga Nikolajeva, Vanderson Rocha, Robert Danby, Annalisa Ruggeri, Fernanda Volt, Etienne Baudoux, Susana G Gomez, Gezine Kögler, Jerome Larghero, Lucilla Lecchi, Mar Sanchez Martinez, Cristina Navarrete, Fabienne Pouthiers, Sergio Querol, Chantal Kenzey, Richard Szydlo, Eliane Gluckman, Alejandro Madrigal
Several studies have reported an impact of the adult haematopoietic stem cells donors cytomegalovirus (CMV) serostatus on allogeneic haematopoietic cell transplantation (HCT) outcomes. Limited data, however, are available on the impact of cord blood unit (CBU) CMV serostatus on allogeneic umbilical cord blood transplantation (UCBT) outcomes. We analysed, retrospectively, the impact of CBU CMV serostatus on relapse incidence (RI) and 2-year non-relapse mortality (NRM) of single-unit CBU transplantation for acute leukaemia...
July 4, 2017: Biology of Blood and Marrow Transplantation
journal
journal
20050
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"